Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment

(2011) G. Juliusson et al.   BLOOD

When a gold standard is made of tin

(2010) G. J. Schiller   BLOOD

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

(2010) Utz Krug et al.   LANCET

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

(2008) S. Faderl et al.   BLOOD